Prophylactic use of urokinase in children with Primary nephrotic syndrome can prevent VTE: Study

A study was done to analyze the clinical effect of urokinase on the prevention of thrombosis in children with primary nephrotic syndrome. A total of 370 children diagnosed with primary nephrotic syndrome (PNS) in the Children’s Hospital of Soochow University and Zibo Maternal and Child Health Hospital from January 2018 to December 2022 were selected as the research objects. The patients were divided into a urokinase adjuvant therapy group and a non-urokinase adjuvant therapy group according to the application of drugs. The clinical data of the children were collected, including sex, age, drug application, bleeding during treatment, and telephone follow-up, to record whether thromboembolism occurred in the acute stage and remission stage. The clinical pattern of PNS, renal biopsy, histopathological type, and related laboratory indexes before and after treatment were recorded.

Results: A total of 313 patients were treated with urokinase and 57 patients were not. More thrombotic events were observed in the non-urokinase group compared to the urokinase group(2 versus 0 episodes, p = 0.02). The thrombotic events observed included one patient who had a pulmonary embolism combined with right ventricular thrombosis and another who had intracranial venous thrombosis. More minor bleeding events occurred in the urokinase group compared to the non-urokinase group(7 versus 1 episode, p = 1.0). No major bleeding events occurred in either group. The rational prophylactic use of urokinase anticoagulation in children with PNS can prevent the formation of thromboembolism and has good safety.

Reference:

Wang, Z., Wang, N., Chen, R. et al. Urokinase prophylactic anticoagulation in children with nephrotic syndrome: a multicenter retrospective cohort study. BMC Nephrol 25, 68 (2024). https://doi.org/10.1186/s12882-024-03502-4